

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

Daiichi Sankyo Establishes New Vaccine Research Unit in Japan

Tokyo, Japan (November 1, 2011) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has established a new Japanese vaccine research unit to be located in its Kasai R&D Center (Edogawa-ku, Tokyo).

Daiichi Sankyo has been strengthening and expanding its vaccine business in line with the Hybrid Business Model featured in its 2nd Mid-term Business Management Plan (FY2010-2012). In April 2011, Daiichi Sankyo set up a research unit inside the National Institute of Biomedical Innovation and is already performing exploratory vaccine research and continuously reinforcing and expanding R&D for new adjuvants.

Through the establishment of its new vaccine research unit, Daiichi Sankyo aims to enhance and broaden exploratory research for vaccines to prevent infectious diseases and to make pharmacological assessments for vaccines (immunogenicity of candidate antigens and ability to fend off infection).

Now, with two vaccine research units and partnerships with organizations inside and outside of the Group, Daiichi Sankyo is poised to fully realize its dedication to producing new vaccines through continuing research efforts and to supplying safe and effective existing vaccines to the healthcare professionals and other persons in Japan who are waiting for them.

###